Skincare company BeautyHealth (NASDAQ:SKIN) will be reporting results tomorrow afternoon. Here’s what you need to know.
BeautyHealth missed analysts’ revenue expectations by 8% last quarter, reporting revenues of $90.59 million, down 22.9% year on year. It was a disappointing quarter for the company, with revenue guidance for next quarter missing analysts’ expectations.
Is BeautyHealth a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting BeautyHealth’s revenue to decline 21.1% year on year to $76.82 million, a reversal from the 9.7% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.05 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BeautyHealth has missed Wall Street’s revenue estimates three times over the last two years.
Looking at BeautyHealth’s peers in the personal care segment, some have already reported their Q3 results, giving us a hint as to what we can expect. e.l.f. delivered year-on-year revenue growth of 39.7%, beating analysts’ expectations by 4%, and Herbalife reported a revenue decline of 3.2%, falling short of estimates by 1%. e.l.f. traded up 11.5% following the results while Herbalife was also up 10.2%.
Read our full analysis of e.l.f.’s results here and Herbalife’s results here.
Investors in the personal care segment have had steady hands going into earnings, with share prices flat over the last month. BeautyHealth is up 3.8% during the same time and is heading into earnings with an average analyst price target of $1.96 (compared to the current share price of $1.63).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefitting from the rise of AI, available to you FREE via this link.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。